Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
TC BioPharm Ltd
TCBP
Healthcare
Biotechnology
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious...
diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:TCBP)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 04, 2024 8:32am
New Press Release - TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies
EDINBURGH, Scotland, April 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 02, 2024 8:31am
New Press Release - TCBP Increasing Treatment Capacity with Expanded Manufacturing Process
Developing streamlined approach to reduce cost per patient by 85%EDINBURGH, Scotland, April 2, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for...
read article.
Fintech Select LTD. Publishes Results for Fiscal Year 2023
posted May 01, 2024 9:00am by
Fintech Select Ltd.
-
|
Under the leadership of Fintech Select's management, the Company achieved a significant milestone in revenue generation, reaching $3,822,182 for fiscal year 2023, compared to $2,587,867 in 2022. Management is confident this 47% increase on a year-over-year basis ...read more
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Mar 20, 2024 8:43am
TCBP...might be worth another shot here
On watch ...again
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 19, 2024 8:30am
New Press Release - TCBP Adjourns General Meeting Until a Later Date
EDINBURGH, Scotland, March 19, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has adjourned...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 18, 2024 8:30am
New Press Release - TCBP Announces Exercise of Series D Warrants For Cash
• Company receives gross proceeds of $1.26 M from transactionEDINBURGH, Scotland, March 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer...
read article.
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Mar 11, 2024 3:23pm
RE:TCBP....don't take the bait !!!!!!!!!!
Told ya....$1.67 now 35 mins til close
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Mar 11, 2024 3:08pm
TCBP....don't take the bait !!!!!!!!!!
This is finished....$1.85
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Mar 11, 2024 1:48pm
TCBP....2nd downside target breached ...now at $1.70
Next !!!!!!!!!!!!!!!!!!!!!!!!!!
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Mar 11, 2024 1:32pm
TCBP.....1st downside target breached....now $1.80
Next !!!!!!!!!!!!!!!!!!!!!!!!!!
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Mar 11, 2024 1:19pm
TCBP.....early a.m runner on no news... Sub $2 now
2 scalps....now in PB mode Targets to the downside are ..... $1.88 ....$1.75....$1.53 Good luck....Me no position
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Feb 09, 2024 9:12am
RE:TCBP...early a.m runner on No News
Quick DD....Co regained NASDAQ compliance and Closed P.O recently ...January P.O was at $2 Your call
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Feb 09, 2024 9:06am
TCBP...early a.m runner on No News
big volume on this "thinner"....$1.59 On watch need more DD
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 07, 2023 8:30am
New Press Release - TC BioPharm Shifts Focus to FDA Clinical Trials
Company to explore US IND pathway for additional combination trialsEDINBURGH, Scotland, March 7, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 23, 2023 8:30am
New Press Release - TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer
EDINBURGH, Scotland, Feb. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Dr. Michael Leek to the...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 21, 2023 8:30am
New Press Release - TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T cell Therapies
EDINBURGH, Scotland, Feb. 21, 2023 /PRNewswire/ -- TC BioPharm(Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today the publication of a paper...
read article.
Prev
1
2
3
4
5
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company